Monopar Starts Rolling NDA Submission for ALXN1840 in Wilson Disease

Monopar Therapeutics said it has begun a rolling submission of a New Drug Application to the FDA for ALXN1840 (tiomolibdate choline) for Wilson disease, and has submitted its first completed sections. The filing is a regulatory milestone; approval is not assured, and the company says the drug could receive a pediatric Priority Review Voucher if approved.

Key points

• Monopar has initiated a rolling NDA submission for ALXN1840 with the FDA and has submitted the first completed sections.
• The FDA authorized the rolling submission, which lets completed sections be reviewed while remaining sections are finalized.
• ALXN1840 received Rare Pediatric Disease designation from the FDA in June 2026, which could allow a pediatric Priority Review Voucher at approval.

The filing

Items reported: 7.01 Regulation FD Disclosure

Read the filing on SEC.gov ↗

Written by AI on Nov 9, 2026, 8:53 AM ET, from this filing only. Written later: this filing was briefed after the fact, when past filings were added to the site, so the brief may be read with hindsight; the filing itself is the record of what was known on July 22, 2026.

Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.